



NeuroMetrix Reports Clinical Studies Recently Published on DPNCheck®

March 5, 2020

WOBURN, Mass., March 05, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the recent publication of three additional DPNCheck clinical studies. DPNCheck is a point-of-care test that provides accurate and cost-effective screening, diagnosis and monitoring of peripheral neuropathies such as diabetic peripheral neuropathy (DPN).

Automated Measurement of Sural Nerve Conduction is a Useful Screening Tool for Peripheral Neuropathy in Type 1 Diabetes Mellitus. Papanas et al. *Rev Diabet Stud.* 2019. <https://www.ncbi.nlm.nih.gov/pubmed/31509155>

The diagnostic accuracy of DPNCheck was assessed in 53 patients with type 1 diabetes with Neuropathy Disability Score (NDS) as the reference method. The study authors concluded "... the findings of this study suggest that the NC-sta® DPNCheck™ device yields high sensitivity and specificity for the diagnosis of DPN in T1DM ... Overall, there appears to be a role for the NC-sta® DPNCheck™ device for more widespread DPN screening in both diabetes types."

Validity and reliability of a point-of-care nerve conduction device in diabetes patients. Shibata et al. *J Diabetes Investig.* 2019. <https://www.ncbi.nlm.nih.gov/pubmed/30659760>

DPNCheck results were compared to traditional nerve conduction studies in 57 patients with diabetes (56 with type 2). The study authors concluded, "The point-of-care device has excellent reproducibility and good agreement with standard electromyography system. The device might be useful to evaluate diabetic polyneuropathy."

A PRPH splice-donor variant associates with reduced sural nerve amplitude and risk of peripheral neuropathy. Bjornsdottir et al. *Nat Commun.* 2019. <https://www.ncbi.nlm.nih.gov/pubmed/30992453>

DPNCheck was used as the outcome measure in a large genome-wide association study between sural nerve conduction amplitude and velocity in 7045 subjects. The study demonstrated that individuals with a variant in the PRPH (Peripheren) gene have a higher risk of early-onset axonal polyneuropathy.

"These three recently published studies contribute to the growing body of research that validates the technical and diagnostic accuracy of DPNCheck and adds to its credibility as a primary outcome measure in clinical trials and epidemiological studies," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "There are now over 30 peer-reviewed publications assessing DPNCheck clinical performance or its use as an objective peripheral neuropathy outcome."

About DPNCheck

DPNCheck is a fast, accurate, and quantitative nerve conduction test that is used to evaluate peripheral neuropathies such as diabetic peripheral neuropathy (DPN). It is designed to be used by clinicians at the point-of-care to objectively detect, stage, and monitor DPN. For more information, please visit www.dpncheck.com.

About NeuroMetrix

NeuroMetrix is a leading developer of diagnostic and therapeutic neurostimulation-based medical devices. DPNCheck® is a point-of-care diagnostic test for peripheral neuropathies such as diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. ADVANCE™ is a point-of-care nerve conduction study that evaluates multiple nerves including the median nerve, which is affected in carpal tunnel syndrome. Quell® is a wearable neurostimulation device for symptomatic relief of chronic pain that is available over-the-counter. For more information, please [visit NeuroMetrix.com](http://www.NeuroMetrix.com).

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.



Source: NeuroMetrix, Inc.